Kidswell Bio Co., Ltd.

Gene Techno Science Co., Ltd. was established in Kita-ku, Sapporo, with capital of 10 million yen to develop the results of research on the functions of immune-related proteins at the Institute for Genetic Medicine, Hokkaido University, as diagnostic and therapeutic products, and to provide contract services for drug development.

Formed the “Bio Infomatics Sapporo Consortium” with HOKUDO Co., Ltd., Shinyaku Development Research Institute Co., Ltd., Nippon Laser Electronics Co., Ltd., and Immuno-Biological Laboratories Co., Ltd.

Established a research laboratory at the Hokkaido Center of the National Institute of Advanced Industrial Science and Technology (AIST), strengthened research and development of new biologics, and began considering entry into the biosimilar business.

Established a new laboratory at the Hokkaido Center of the National Institute of Advanced Industrial Science and Technology (Toyohira-ku, Sapporo) to strengthen research and development of biopharmaceuticals, and began considering entry into the biosimilar business.

Received a grant from the Ministry of Economy, Trade and Industry for creative technology research and development under the project “Development of an Ataxia Model Caused by Cerebellar Dysfunction.”

Received a joint research and development grant from the Hokkaido Small Business Support Center, a foundation, together with Hokudo Co., Ltd., Shinyaku Kaihatsu Kenkyusho Co., Ltd., and Immuno-Biological Laboratories Co., Ltd., for the project “Discovery of Novel Genes for Disease Models for Drug Discovery and Development.”

Certified by the National Institute of Advanced Industrial Science and Technology as an “AIST Venture Company (Outcome-Creating Type).”

Relocated the head office to the research laboratory.

Licensed out an anti-α9 integrin antibody to Kaken Pharmaceutical Co., Ltd. in the new biologics business.

Signed a joint development agreement with Fuji Pharma Co., Ltd. for G-CSF in the biosimilar business.

In-licensed the G-CSF-producing cells and basic production technology from Toa Pharmaceutical Co., Ltd.

In the biosimilar business, licensed in G-CSF-producing cells and basic production technology from Toa Pharmaceutical Co., Ltd.

Relocated the head office to Chuo-ku, Sapporo.

Relocated the research laboratory to the Institute for Genetic Medicine at Hokkaido University.

Relocated the laboratory to the Institute for Genetic Medicine, Hokkaido University (Kita-ku, Sapporo).

Established a new Tokyo office in Chuo-ku, Tokyo.

Fuji Pharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd. obtained domestic manufacturing and marketing approval for G-CSF (launched in May 2013), and the company listed its shares on the Tokyo Stock Exchange Mothers market.

Fujipharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd. obtained domestic marketing and manufacturing approval (launched in May 2013), and the company listed its shares on the Tokyo Stock Exchange Mothers market.

Fujipharma Co., Ltd. and Mochida Pharmaceutical Co., Ltd. obtained domestic marketing and manufacturing approval for G-CSF, which was jointly developed with Fujipharma Co., Ltd.

Listed its shares on the Tokyo Stock Exchange Mothers market.

G-CSF, jointly developed with Fujipharma Co., Ltd., was launched.

G-CSF has been launched (launched in May 2013)

Entered into a capital and business alliance with ITOCHU Chemical Frontier Corporation.

In the biosimilar business, entered into a capital and business alliance with ITOCHU CHEMICAL FRONTIER Corporation.

Relocated the research laboratory to the Center for Development of Advanced Platforms for Molecular and Cellular Biotechnologies, Institute for the Advancement of Higher Education, Hokkaido University.

Relocated the laboratory to the Center for Promotion of the Research and Development Platform for Functional Biomolecules, Creative Research Institution, Hokkaido University (Kita-ku, Sapporo).

Signed a joint development agreement with Sanwa Kagaku Kenkyusho Co., Ltd. for darbepoetin alfa.

In the biosimilar business, entered into a joint development agreement for darbepoetin alfa with Sanwa Kagaku Kenkyusho Co., Ltd.

Entered into a joint nucleic acid business agreement with Gene Design Inc. to commercialize a nucleic acid drug development platform

Entered into a capital and business alliance with ORTHOREBIRTH Co., Ltd., which conducts research and development on artificial bones

DyDo DRINCO, Inc. made a capital investment

Daido Drinco Co., Ltd. made an equity investment with a view to collaboration in the medical and healthcare-related businesses.

Entered into a basic agreement on a business alliance with Mochida Pharmaceutical Co., Ltd. for the joint development and sale of biosimilars in the cancer treatment field

Relocated the Tokyo office to Chuo-ku, Tokyo

Entered into a basic agreement on a capital and business alliance with Senju Pharmaceutical Co., Ltd. for the joint development and commercialization of biosimilars in the ophthalmic treatment field.

Noritsu Koki Group made a tender offer for the Company's common shares, and a capital and business alliance agreement was entered into

Entered into a joint commercialization agreement with Senju Pharmaceutical Co., Ltd. for biosimilars in the ophthalmic treatment field

Entered into a basic agreement with Changchun Changsheng Bio-technology Co., Ltd. (Changsheng Bio) toward commercializing biosimilars in the Chinese market

Joined the Biosimilars Council

Entered into a capital and business alliance agreement with Japan Regenerative Medicine Co., Ltd. (JRM) concerning the commercialization of regenerative medicine using cardiac stem cells

Entered into a capital and business alliance agreement with JSR Corporation.

Entered into a joint commercialization agreement with Mochida Pharmaceutical Co., Ltd. for biosimilars in the cancer treatment field.

Entered into a joint research agreement with Juntendo University on the induction of immune tolerance

Entered into a capital and business alliance agreement with Itochu Chemical Frontier Corporation for the development of new biosimilars

Entered into a capital and business alliance agreement with NanoCarrier Co., Ltd. and Noritsu Koki Co., Ltd.

Entered into a joint research agreement with chromocenter Inc. to establish fundamental technologies for developing high-producing cell lines

Entered into a joint research agreement with U.S.-based SOLA Biosciences, LLC to establish foundational technologies aimed at developing high-producing cell lines.

Launched commissioned research with GPC Research Institute Co., Ltd. to establish fundamental technologies for developing high-producing cell lines

Made Cell Technology Co., Ltd. a wholly owned subsidiary through a share exchange

Entered into a joint research and development agreement with ORTHOREBIRTH Co., Ltd. to develop treatments for cleft lip and palate

Changed the head office location to Chuo-ku, Tokyo

Made Japan Regenerative Medicine Co., Ltd. a wholly owned subsidiary by acquiring its shares from Noritsu Koki Co., Ltd.

Transferred all shares of Cell Technology Co., Ltd., removing it from the scope of consolidation

The company name was changed to Kidswell Bio Co., Ltd.